Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran

  • Mehrabani, Davood (Stem Cell and Transgenic Technology Research Center, Department of Pathology, Shiraz University of Medical Sciences) ;
  • Shamsdin, Seyedeh Azra (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences) ;
  • Dehghan, Alireza (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences) ;
  • Safarpour, Alireza (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Colon cancer (CRC) is perhaps the second most common cause of cancer mortality. This study determined the clinical significance of serum vascular endothelial growth factor (VEGF) and serum complement 3a (C3a) levels in patients with CRC in Fars province, southern Iran. Materials and Methods: Between June 2010 and June 2012, 110 patients with CRC of both genders and different age groups were divided into 3 groups. Group A included patients who had just undergone surgery; Group B had undergone chemotherapy after surgery; and Group C had undergone chemotherapy and radiotherapy after surgery. Twenty one healthy subjects with normal colonoscopy were considered as a control group. ELISA was undertaken to determine VEGF and C3a levels before and after treatment measures. Results: The mean age of patients was $53.9{\pm}14.1$ years. Considering VEGF level, a significant decrease was visible after treatment measures in groups A and B, but not Group C. For VEGF level, the difference was not statistically significant between two genders and various age groups before and after treatment. No significant difference was found for VEGF level between patients and normal group before any treatment. Regarding C3a levels in 101 subjects, they significantly decreased after treatment measures. Before and after treatment, the difference was statistically significant between two genders, but was not statistically significant among various age groups. Conclusions: As VEGF and C3a levels were significantly lower in patients after treatment, these may be beneficial markers in assessment of CRC therapy especially in early stages.

Keywords

References

  1. Ahluwalia A, Jones MK, Matysiak-Budnik T, et al (2014). VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? Current Pharmaceutical Design, 20, 1041-4. https://doi.org/10.2174/1381612819999131218175905
  2. Ahluwalia A, Jones MK, Szabo S, et al (2013). Ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. Biochem Biophys Res Commun, 437, 515-20. https://doi.org/10.1016/j.bbrc.2013.06.096
  3. Cetin B, Kaplan MA, Berk V,et al (2012). Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factortargeting agents. Asian Pac J Cancer Prev, 13, 1059-63. https://doi.org/10.7314/APJCP.2012.13.3.1059
  4. Cunningham D, Atkin W, Lenz IJ, et al (2010). Colorectal cancer, Lancet, 375, 1030-47. https://doi.org/10.1016/S0140-6736(10)60353-4
  5. Dube C, Rostom A, Lewin O, et al (2007). US Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: A systemic review prepared for the US Preventive Services Task Force. Ann Int Med, 146, 365-75. https://doi.org/10.7326/0003-4819-146-5-200703060-00009
  6. Enewold L, Horner MJ, Shriver CD (2014). Socioeconomic disparities in colorectal cancer mortality in the United States, 1990-2007. J Community Health, 39, 760-6. https://doi.org/10.1007/s10900-014-9824-z
  7. Fauci A, Rasper D, Longo D, et al (2008). Harissons Principles of Internal Medicine. Seventeenth edition. New York: McGraw Hill.
  8. Ferlay J, Bray F, Pisani P, et al (2011). Cancer Incidence, Mortality and Prevalence Worldwide. GLOBOCAN, IARC Cancer Base, 5. version 2.0. http://www-dep.iarc.fr/ Accessed 10 July.
  9. Greene FLPD, Fleming ID, Fritz A (2002). AJCC Cancer Staging Manual. 6th ed., New York: Springer; p. 421.
  10. Habermann JK, Roblick UJ, Luke BT, et al (2006). Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology, 131, 1020-9. https://doi.org/10.1053/j.gastro.2006.07.011
  11. Kanmura S, Uto H, Sato Y, et al (2010). The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol, 45, 459-67. https://doi.org/10.1007/s00535-009-0160-5
  12. Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401. https://doi.org/10.7314/APJCP.2012.13.12.6397
  13. Kargi A, Yalcin AD, Erin N, et al (2012). Erratum to IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer. Clin Lab, 58, 1103-7.
  14. Kyutoku M, Nakagami H, Koriyama H, et al (2013). Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep, 3, 3380.
  15. Levin B, Brooks D, Smith RA, et al (2003). Emerging technologies in screening for colorectal cancer: CT colonography. immunochemical fecal occult blood test and stool screening using molecular markers. CA Cancer J Clin, 53, 44-5. https://doi.org/10.3322/canjclin.53.1.44
  16. Lieberman DA, Weiss DG, Bond JH, et al (2000). Use of colonoscopy to screen asymptomalic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med, 343, 162-8. https://doi.org/10.1056/NEJM200007203430301
  17. Lowery JT, Horick N, Kinney AY, et al (2014). A randomized trial to increase colonoscopy screening in members of high risk families in the Colorectal Cancer Family Registry and Cancer Genetics Network. Cancer Epidemiol Biomarkers Prev, 23, 601-10. https://doi.org/10.1158/1055-9965.EPI-13-1085
  18. Maher SG, McDowell DT, Collins BC, et al (2011). Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg, 254, 809-16. https://doi.org/10.1097/SLA.0b013e31823699f2
  19. Mandel JS, Church TR, Bond JH, et al (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Eng J Med, 343, 1603-7. https://doi.org/10.1056/NEJM200011303432203
  20. Mehrabani D, Almasi-Hashiani A (2012a). Evaluation of the 5-year survival rate and demographic factors in colorectal cancer patients. Zanjan Med J, 20, 12-19.
  21. Mehrabani D, Almasi-Hashiani A, Moshfeghi K, et al (2012b). Survival rate and its predictors in colorectal cancer patients, Southern Iran. Middle-East J Sci Res, 12, 1072-7.
  22. Mehrabani D, Tabei SZ, Heydari ST, et al (2008). Cancer occurrence in Fars Province, Southern Iran. Iran Red Crescent Med J, 10, 314-22.
  23. Miyazaki S, Kikuchi H, Iino I, et al (2014). Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer, 135, 295-307. https://doi.org/10.1002/ijc.28686
  24. Pignone M, Rich M, Teutsch SM, et al (2002). Screening for colorectal cancer in adults at average risk: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med, 137, 132-41. https://doi.org/10.7326/0003-4819-137-2-200207160-00015
  25. Qian LY, Li P, Li XR, et al (2012). Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases. Asian Pac J Cancer Prev, 13, 3967-71. https://doi.org/10.7314/APJCP.2012.13.8.3967
  26. Saberi-Firoozi M, Kamali D, Yousefi M, et al (2007). Clinical characteristics of colorectal cancer in Southern Iran, 2005. Iran Red Crescent Med J, 9, 209-11.
  27. Safarpour AR, Hosseini SV, Mehrabani D (2013). Epidemiology of Inflammatory Bowel Diseases in Iran and Asia; A Mini Review. Iran J Med Sci, 38, 140-9.
  28. Smith RA, Eschenbach AC, Wender R (2001). ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee: American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin, 51, 38-75. https://doi.org/10.3322/canjclin.51.1.38
  29. Szajewski M, Kruszewski WJ, Lakomy J (2014). VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. Oncol Rep, 31, 125-30.
  30. Talaiezadeh A, Tabesh H, Sattari A, et al (2013). Cancer incidence in southwest of Iran: First report from Khuzestan population-based cancer registry, 2002-2009. Asian Pac J Cancer Prev, 14, 7517-22. https://doi.org/10.7314/APJCP.2013.14.12.7517
  31. Wang Y, Han G, Wang K, et al (2014). Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF. Cancer Res, 74, 716-26. https://doi.org/10.1158/0008-5472.CAN-13-1459
  32. Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905. https://doi.org/10.1038/sj.bjc.6603188
  33. Winawer SJ, Flehinger BJ, Scholtenfeld D, et al (1993). Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst, 85, 1311-8. https://doi.org/10.1093/jnci/85.16.1311
  34. Yousefi AR, Karimi MH, Shamsdin SA, et al (2013). PD-1 Gene polymorphisms in Iranian patients with colorectal cancer. Lab Medicine, 44, 23-6.
  35. Zubero MB, Arana-Arri E, Pijoan JI, et al (2014). Populationbased colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol, 4, 175.

Cited by

  1. Association of XRCC1 Arg399Gln Polymorphism with Colorectal Cancer Risk: A HuGE Meta Analysis of 35 Studies vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3285
  2. Ganglioside as a Therapy Target in Various Types of Cancer vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1643
  3. Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway vol.12, pp.6, 2016, https://doi.org/10.3892/ol.2016.5319
  4. Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls pp.1532-4311, 2018, https://doi.org/10.1080/08820139.2018.1480030